Director at Klotho Neurosciences (KLTO) awarded 350,000 shares
Rhea-AI Filing Summary
Klotho Neurosciences, Inc. reported that director Shalom Hirschman acquired 350,000 shares of Common Stock on March 4, 2026. The shares were received as a grant under the company’s Equity Incentive Plan and carried a stated price of $0.00 per share.
Following this equity award, Hirschman’s direct ownership increased to 908,873 shares of Common Stock, according to the Form 4 disclosure.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 350,000 shares
Net Buy
1 txn
Insider
Hirschman Shalom
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 350,000 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 908,873 shares (Direct)
Footnotes (1)
- F1. The Reporting person received the shares as a grant under the company's Equity Incentive Plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did Klotho Neurosciences (KLTO) disclose for Shalom Hirschman?
Klotho Neurosciences disclosed that director Shalom Hirschman received a grant of 350,000 shares of Common Stock. The award was reported on Form 4 and reflects an equity incentive grant rather than an open-market purchase or sale.
What does the transaction code on Shalom Hirschman’s KLTO Form 4 indicate?
The transaction code is classified as a grant, award, or other acquisition. This means the 350,000 Klotho Neurosciences shares were issued to Shalom Hirschman as an equity incentive grant rather than being bought or sold on the market.